Moderna Shares Plunge 20% After Report of Cancer Vaccine Data Leak

According to reports, a third party leaked a dataset related to the cancer vaccine being co-developed by Moderna and Merck just before the trial results were due to be published. In response to the leak reports, both companies' share prices fell sharply, with Moderna shares reportedly dropping by about 20%, as noted in the article headline.

The linked article reportedly showed results indicating that the group receiving the vaccine in combination with Keytruda reduced the "probability of death or recurrence by 42%" compared with the Keytruda-only group. These figures are based on information disclosed before an official announcement by those involved, so they need to be checked against the final published data.

This incident is an example of how leaked clinical trial data can affect markets and underscores the renewed importance of information management in the contexts of drug development and investment. The original story circulated by sharing an Investors Business Daily report on Hacker News, and it is important to verify the final formal announcement and any official comments from the two companies.

This article reports on the leak and market reaction and does not offer an interpretation of clinical results or definitive conclusions about treatment efficacy. Until a formal peer-reviewed publication or an official corporate release is issued, the figures and conclusions reported here should be treated as preliminary information.